Dusa Pharmaceuticals (DUSA) 10-Q2009 Q1 Quarterly report

Filed: 12 May 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: APB, appointing, authoritative, blue, broker, Burn, Canadian, cancel, candidate, clarity, commensurate, copyright, curtail, disruption, distressed, distributor, divestiture, dollar, domestic, earn, Eventsto, faith, FAS, flow, FSP, headcount, inactive, instrument, jeopardized, Kerastick®And, lot, methodology, noncredit, nonfinancial, occurrence, Opinion, Pacific, payout, postpone, raw, real, recall, recession, registration, revert, rollforward, scheduled, scrutiny, shortfall, slightly, Slowdown, stability, thirteen, tightening, timeframe, title, tradeshow, understand, unilateral, unrecognized, unvested, variable, vast, wholesale

Removed: abbreviated, account, allocation, Amide, amortization, anthralin, ARB, Asian, averaging, basal, batch, begin, Brazilian, cavity, Central, channel, chemoprevention, Chile, CMS, Colombia, compensated, compounded, compounding, confirm, consolidation, convenience, country, curbing, DCP, decide, defer, Derma, description, direct, Division, DNC, ease, educate, eliminating, encouraging, established, execution, expiring, exploring, facilitate, false, favorably, February, flat, force, forward, guide, hindered, hiring, illegal, impacting, improvement, incremental, Institute, intangible, integration, internationally, intervene, intrinsic, introduction, Japan, KFDA, Korean, lack, Lanham, launching, law, learn, Learned, leasing, maintained, measuring, medicinal, move, NCI, negative, Network, noncontrolling, Participant, partnership, past, percent, planning, Plastic, precursor, prepare, proactive, promise, prospectively, protocol, published, purpose, recharacterized, recognize, rectify, referred, residual, responsibility, retirement, revised, revising, role, Scandinavia, select, serve, set, settled, shipment, situation, size, South, spend, standard, stated, strongly, submit, subsidiary, suitability, supplemental, Surgery, surrender, thereto, training, unconditionally, unexpected, Union, unsecured, upfront, Valhalla, vehicle, vested, wholly, widespread, worked, York, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

DUSA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32(A)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DUSA Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2009, as filed with the Securities and Exchange Commission (the “Report”), I, Robert F. Doman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



	/s/ Robert F. Doman
	Robert F. Doman
	President and Chief Executive Officer (principal executive officer)

Date: May 12, 2009

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.